PE20070839A1 - Derivados de indolobenzazepina como inhibidores de ns5b de vhc - Google Patents

Derivados de indolobenzazepina como inhibidores de ns5b de vhc

Info

Publication number
PE20070839A1
PE20070839A1 PE2006001105A PE2006001105A PE20070839A1 PE 20070839 A1 PE20070839 A1 PE 20070839A1 PE 2006001105 A PE2006001105 A PE 2006001105A PE 2006001105 A PE2006001105 A PE 2006001105A PE 20070839 A1 PE20070839 A1 PE 20070839A1
Authority
PE
Peru
Prior art keywords
alkyl
cyclohexil
carboxamide
piperidinyl
inhibitors
Prior art date
Application number
PE2006001105A
Other languages
English (en)
Inventor
Carl P Bergstrom
John A Bender
Robert G Gentles
Thomas W Hudyma
Scott W Martin
Kap-Sun Yeung
Katharine A Grant-Young
Xiaofan Zheng
Yong Tu
Alicia Regueiro-Ren
John F Kadow
Piyasena Hewawasam
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20070839A1 publication Critical patent/PE20070839A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

REFERIDA A UN COMPUESTO INDOLOBENZAZEPINA DE FORMULA (I), DONDE R1 ES COOR6 OCONR7R8; R2 ES CONR9R10, NHCO(CICLOALQUILO), NHCOR14, ENTRE OTROS; R3 ES H O ALQUILO C1-C6; R4 ES H, HALO, ALQUILO C1-C6, ALCOXI C1-C6, BENCILOXI, ENTRE OTROS; R5 ES CICLOALQUILO C5-C7; R9 ES CICLOALQUILO C3-C7, DIHIDROXIALQUILO, (CHO)ALQUILO C1-C6, ENTRE OTROS; R10 ES H, ALQUILO C1-C6, DIHIDROXIALQUILO, AMINOALQUILO, ENTRE OTROS; R14 ES AZETIDINA, PIRROLIDINILO, PIPERIDINILO, PIPERAZINILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 1-CICLOHEXIL-N-[(DIMETILAMINO)SULFONIL]3-(3-OXO-3-(4-(2-OXOPIRROLIDIN-1-IL)PIPERIDIN-1-IL)PROPIL)-2-FENIL-3H-INDEN-5-CARBOXAMIDA, 13-CICLOHEXIL-N-(2-FURANILMETIL)-6-[[4-(4-MORFOLINIL)-1-PIPERIDINIL]CARBONIL]-7H-INDOLO[2,1-a][2]BENZAZEPIN-10-CARBOXAMIDA, 13-CICLOHEXIL-6-[[4-(4-MORFOLINIL)-1-PIPERIDINIL]CARBONIL]-N-[[(2R)-TETRAHIDRO-2-FURANIL]METIL]-7H-INDOLO[2,1-a][2]BENZAZEPIN-10-CARBOXAMIDA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE LA PROTEINA NS5B DEL VIRUS DE LA HEPATITIS C (VHC)
PE2006001105A 2005-09-13 2006-09-12 Derivados de indolobenzazepina como inhibidores de ns5b de vhc PE20070839A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US71669305P 2005-09-13 2005-09-13
US77150106P 2006-02-08 2006-02-08

Publications (1)

Publication Number Publication Date
PE20070839A1 true PE20070839A1 (es) 2007-09-10

Family

ID=37637507

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001105A PE20070839A1 (es) 2005-09-13 2006-09-12 Derivados de indolobenzazepina como inhibidores de ns5b de vhc

Country Status (5)

Country Link
US (1) US7473688B2 (es)
AR (1) AR055165A1 (es)
PE (1) PE20070839A1 (es)
TW (1) TW200745120A (es)
WO (1) WO2007033175A1 (es)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7795247B2 (en) 2004-10-26 2010-09-14 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetracyclic indole derivatives as antiviral agents
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7399758B2 (en) * 2005-09-12 2008-07-15 Meanwell Nicholas A Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
KR20080059270A (ko) * 2005-09-30 2008-06-26 싸이넥시스, 인크. Ｃ형 간염 감염의 치료 및 예방을 위한 방법 및 제약조성물
US7456165B2 (en) * 2006-02-08 2008-11-25 Bristol-Myers Squibb Company HCV NS5B inhibitors
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
US7456166B2 (en) * 2006-05-17 2008-11-25 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521443B2 (en) * 2006-05-17 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7521441B2 (en) * 2006-05-22 2009-04-21 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2007140200A2 (en) * 2006-05-25 2007-12-06 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
ES2343914T3 (es) * 2006-05-25 2010-08-12 Bristol-Myers Squibb Company Inhibidores de ns5b de hcv de indolobenzazepina condensada con ciclopropilo.
US7452876B2 (en) * 2006-06-08 2008-11-18 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
US7541351B2 (en) * 2007-01-11 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7541352B2 (en) * 2007-02-02 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7517872B2 (en) * 2007-02-22 2009-04-14 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7998951B2 (en) * 2007-03-05 2011-08-16 Bristol-Myers Squibb Company HCV NS5B inhibitors
US7541353B2 (en) * 2007-03-14 2009-06-02 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7521444B2 (en) * 2007-03-14 2009-04-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7547690B2 (en) * 2007-03-14 2009-06-16 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538102B2 (en) * 2007-03-14 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US7538103B2 (en) * 2007-03-15 2009-05-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US20080255038A1 (en) * 2007-04-11 2008-10-16 Samuel Earl Hopkins Pharmaceutical compositions
WO2009010785A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
US7642251B2 (en) * 2007-08-09 2010-01-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8143243B2 (en) * 2007-08-09 2012-03-27 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US7652004B2 (en) * 2007-08-09 2010-01-26 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2209789B1 (en) * 2007-11-20 2011-11-16 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors
US8129367B2 (en) * 2007-11-21 2012-03-06 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
EA201000948A1 (ru) 2007-12-19 2011-02-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы вирусной полимеразы
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
ES2374870T3 (es) 2008-03-27 2012-02-22 Bristol-Myers Squibb Company Inhibidores de ns5b de vhc de indolobenzadiazepina fusionada con heterocíclicos aromáticos.
JP2011515486A (ja) * 2008-03-27 2011-05-19 ブリストル−マイヤーズ スクイブ カンパニー Ｃ型肝炎の治療用化合物
US8119628B2 (en) * 2008-03-27 2012-02-21 Bristol-Myers Squibb Company Pyrrolidine fused indolobenzadiazepine HCV NS5B inhibitors
US8138171B2 (en) * 2008-03-27 2012-03-20 Bristol-Myers Squibb Company Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors
US8133884B2 (en) * 2008-05-06 2012-03-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
CA2724523A1 (en) * 2008-06-06 2010-01-07 Scynexis, Inc. Novel macrocyclic peptides
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
JP2012514605A (ja) 2009-01-07 2012-06-28 サイネクシス，インコーポレーテッド Ｈｃｖおよびｈｉｖ感染の治療への使用におけるシクロスポリン誘導体
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
WO2010093359A1 (en) * 2009-02-11 2010-08-19 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis c
US8143244B2 (en) 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
WO2010101967A2 (en) 2009-03-04 2010-09-10 Idenix Pharmaceuticals, Inc. Phosphothiophene and phosphothiazole hcv polymerase inhibitors
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
TW201117812A (en) 2009-08-05 2011-06-01 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
EP2513113B1 (en) 2009-12-18 2018-08-01 Idenix Pharmaceuticals LLC 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
JP5918264B2 (ja) 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
BR112013016480A2 (pt) 2010-12-30 2016-09-20 Abbvie Inc macrocíclo da fenantridina inibadores da protease da serina da hepatite c
JP2014502620A (ja) 2010-12-30 2014-02-03 エナンタ ファーマシューティカルズ インコーポレイテッド 大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
LT2968316T (lt) 2013-03-13 2019-10-25 Forma Therapeutics Inc 2-hidroksi-1-{4-[(4-fenilfenil)karbonil]piperazin-1-il}etan-1-ono dariniai ir susiję junginiai, kaip riebalų rūgšties sintazės (fasn) inhibitoriai, skirti vėžio gydymui
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
US20170135990A1 (en) 2014-03-05 2017-05-18 Idenix Pharmaceuticals Llc Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200400963A (en) * 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
EP1719773B1 (en) 2004-02-24 2009-04-15 Japan Tobacco, Inc. Fused heterotetracyclic compounds and use tehreof as hcv polymerase inhibitor
US7153848B2 (en) * 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7348425B2 (en) * 2004-08-09 2008-03-25 Bristol-Myers Squibb Company Inhibitors of HCV replication
CA2585084A1 (en) 2004-10-26 2006-05-04 Immacolata Conte Tetracyclic indole derivatives as antiviral agents
GB0518390D0 (en) 2005-09-09 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds

Also Published As

Publication number Publication date
TW200745120A (en) 2007-12-16
US7473688B2 (en) 2009-01-06
WO2007033175A1 (en) 2007-03-22
AR055165A1 (es) 2007-08-08
US20070078122A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
PE20070839A1 (es) Derivados de indolobenzazepina como inhibidores de ns5b de vhc
AR057810A1 (es) Inhibidores ns5b de vhc de indolobenzazepina fusionados a ciclopropilo y composicion farmaceutica
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
WO2002055496A8 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
CY1111693T1 (el) Αντιιικοι παραγοντες
EA200601849A1 (ru) 4-фениламинохиназолин-6-ил-амиды
CY1109497T1 (el) Παραγωγα θειοφενιου ως αντιβιοτικοι παραγοντες για λοιμωξη/μολυνση φλαβοϊου (flavivirus)
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
AR039209A1 (es) Derivados de indolilmaleimida
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
ATE512961T1 (de) Amorphes nebivolol hydrochlorid und seine herstellung
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
DE60132975D1 (de) Neue substanzen und verbindungen als protease-inhibitoren
DE602005023015D1 (de) Indolderivate als viruzide
NO20056192L (no) Kapaseinhibitorer og anvendelse derav
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
EA200801909A1 (ru) Соединения пиридина для лечения заболеваний, опосредованных действием простагландина
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
CY1106857T1 (el) Βενζαμιδια 4-(αμινομεθυλ)-πιπεριδινης ως 5ht4-ανταγωνιστες
SE0400043D0 (sv) New compounds
PE20091090A1 (es) Derivados de piperidina como agonistas de receptores muscarinicos
SE0403171D0 (sv) New compounds
IL183373A0 (en) 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate

Legal Events

Date Code Title Description
FC Refusal